Rebel Medicine Inc
October 17, 2023
Company Description: Rebel Medicine is a specialty pharmaceutical company headquartered in Salt Lake City, Utah, that leverages drug delivery science to create innovative therapies to address unmet medical needs. Our initial therapeutic focus is non-opioid acute pain management and our flagship product is Alevatrix™, an injectable, extended-release bupivacaine gel that provides 3-4 days of non-opioid postoperative pain relief after a single administration. Alevatrix™ is currently in the IND-enabling phase of development with plans to initiate a Phase 2 active-controlled safety and efficacy clinical trial active comparator in a commercially relevant peripheral nerve block indication in Q1 2024. We’ve raised $3M in equity-based funding and $1.8M in non-dilutive funding to date. We are currently raising a Series A round to fund Alevatrix™ clinical development. Our goal is to out-license the Alevatrix™ asset to a strategic partner during clinical development.
CEO/Top Company Official
Lead Product in Development
Alevatrix, an injectable extended-release bupivacaine gel that can provide 3-4 days of non-opioid postoperative pain management. Alevatrix can be used in nearly any surgical scenario via either local instillation or peripheral nerve block routes of administration. We've performed significant pre-clinical validation in highly translational pig models demonstrating 3-4 days of analgesic effect without safety concerns. Alevatrix has extremely low COGS and pricing flexibility necessary to disrupt the current space while maintaining profit margins of 90-95%.
Development Phase of Primary Product
Number Of Unlicensed Products